Abbott), for three months in combination with an oral anti-androgen (AA) Eulexin (Schering-Plough) 250 mg x 3. Thereafter all patients continued on the anti-androgen alone, T Eulexin 250 mg x 3 daily,

2 trials

Sponsors

Scandinavian Prostate Cancer Group (SPCG) (Sweden)

Conditions

Local or locally advanced prostate cancer, pN0, M0 Cancer Malignant neoplasm of prostate

Unknown Phase

A randomised trial comparing hormonal treatment versus combination of hormonal treatment and radiotherapy in locally advanced prostate cancer

Active, not recruitingISRCTN01534787

Scandinavian Prostate Cancer Group (SPCG) (Sweden)Local or locally advanced prostate cancer, pN0, M0 Cancer Malignant neoplasm of prostate

Start: 1996-02-27Target: 880Updated: 2015-01-13

The incidence of residual prostate cancer in patients included in a randomised trial comparing hormonal treatment versus combination of hormonal treatment and radiotherapy in locally advanced prostate cancer

Active, not recruitingISRCTN76301727

Scandinavian Prostate Cancer Group (SPCG) (Sweden)Local or locally advanced prostate cancer, pN0, M0 Cancer Malignant neoplasm of prostate

Start: 2001-03-01Target: 200Updated: 2015-01-13

Related Papers

Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial.

2009-03-1359 citations

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

2008-12-16576 citations